MyNgan Duong and Stephen J. Nicholls Pages 2947 - 2951 ( 5 )
For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.
Atherosclerosis, cardiovascular disease, HDL, lipids, risk factors.
, South Australian Health and Medical Research Institute. PO Box 11060. Adelaide, SA, 5001, Australia.